Mouth Wash: Diphenhydramine | Lidocaine | Antacid

Oral rinse — swish, gargle, and spit: Shake the preparation gently before each use. Measure the prescribed volume (typically 5–10 mL). Swish vigorously throughout the mouth for 1–2 minutes, then gargle if oropharyngeal symptoms are present, then expectorate. Do not swallow — systemic absorption of lidocaine can cause cardiovascular and CNS toxicity if swallowed in large amounts. Do not eat or drink for at least 30 minutes after use to allow the preparation to coat and remain in contact with affected mucosa. Administer every 4–6 hours as prescribed, or before meals to reduce pain while eating. Do not exceed the prescribed frequency.

Dosing frequency and volume are prescriber-determined based on indication and pain severity.

• Typical regimen: 5–10 mL swished and expectorated every 4–6 hours as needed; some protocols schedule before each meal and at bedtime.
• For chemotherapy- or radiation-induced mucositis: use throughout the course of treatment and for 2–4 weeks post-therapy as symptoms persist.
• Beyond-use dating applies to all compounded solutions; do not use past the expiration assigned by the dispensing pharmacy.

• Diphenhydramine: Competitively antagonizes H1 histamine receptors in mucosal and vascular tissue, reducing histamine-mediated vasodilation, edema, and pruritus in inflammatory oral lesions. Also has mild local anesthetic properties due to sodium channel inhibition at higher concentrations.
• Lidocaine (viscous 2%): Blocks voltage-gated sodium channels at mucosal nerve endings, preventing generation and propagation of action potentials. This produces reversible, rapid-onset local anesthesia of the mucosal surfaces in direct contact with the rinse. Onset is within 1–3 minutes; duration approximately 30–60 minutes per application.
• Antacid (Al(OH)₃/Mg(OH)₂): Neutralizes acid and coats mucosal surfaces with a protective buffer film that reduces direct acid-induced irritation. The viscous suspension increases the contact time and distribution of the other active agents on the oral mucosa, enhancing their local bioavailability and efficacy.

Primary indication: Palliative management of oral mucositis pain in patients undergoing chemotherapy and/or radiation therapy for head and neck or hematologic malignancies. Additional uses include aphthous ulcer pain, oropharyngeal pain from herpes simplex stomatitis, and post-procedural oral discomfort. Note: clinical studies have not demonstrated superiority of magic mouthwash over simpler alternatives (e.g., saline rinse) in preventing mucositis or accelerating healing, but significant pain relief benefit is consistently reported.

Prescriber monitoring:

• Assess pain severity and functional eating at each oncology visit
• Monitor for signs of lidocaine toxicity if patients may be inadvertently swallowing large volumes: perioral numbness, metallic taste, dizziness, or cardiac symptoms
• Evaluate for secondary oral candidiasis in immunosuppressed patients (antifungal may need to be added)
• Maintain adequate nutrition and hydration monitoring when mucositis severity impairs oral intake

Contraindications:

• Hypersensitivity to lidocaine, amide local anesthetics, diphenhydramine, or antacid components
• Ingestion in large volumes — risk of lidocaine toxicity (CNS and cardiac)

Warnings & Precautions:

• Do not swallow — instruct all patients emphatically to spit after rinsing; accidental ingestion of significant volumes can lead to lidocaine CNS toxicity (seizures) and cardiovascular effects (arrhythmia)
• Pediatric patients: viscous lidocaine has caused cardiac arrest and death in infants/young children when inadvertently swallowed; use with extreme caution and strict supervision in pediatric populations
• Gag/swallowing reflex impairment: lidocaine anesthesia of the oropharynx may transiently suppress the gag reflex — instruct patients not to eat immediately after use until sensation returns
• Diphenhydramine: may cause drowsiness, especially with concurrent CNS depressants or in elderly patients

Drug Interactions:

• Antacid component may reduce absorption of concurrent oral medications — separate by ≥2 hours
• CNS depressants: additive sedation with diphenhydramine

Common Side Effects: Temporary numbness of the tongue and oropharynx, transient altered taste, mild drowsiness (diphenhydramine); constipation or diarrhea from antacid component; rare staining of teeth with prolonged use.

Store at room temperature (15–25°C), away from heat and direct sunlight. Shake gently before each use as the formulation may settle. Do not freeze. Keep tightly capped. Observe the beyond-use date assigned by Genesis Compounding; compounded solutions typically have shorter beyond-use dates than commercially manufactured products. Keep out of reach of children.

Why do I need to spit this out and not swallow it?

Lidocaine in this preparation is meant to act locally on the mucosal surface. Swallowing significant amounts allows systemic absorption, which can cause numbness throughout the throat, CNS toxicity (dizziness, confusion, seizures), and cardiovascular effects. Always spit after rinsing.

How long will the pain relief last?

Lidocaine's local anesthetic effect typically lasts 30–60 minutes per application. Using the rinse before meals allows patients to eat with less discomfort during this window of analgesia.

Does magic mouthwash prevent mouth sores from forming?

No — clinical evidence does not show that this preparation prevents mucositis or speeds healing. It provides palliative pain management during the course of mucositis caused by chemotherapy or radiation. Continuing prescribed cancer treatment and maintaining oral hygiene are the primary strategies alongside pain management.

Can I add other ingredients to manage a fungal infection?

Prescribers sometimes add nystatin to the formulation for patients at high risk of oral candidiasis. This requires a specific prescription — do not modify the preparation yourself.

Is this FDA-approved?

This compounded mouthwash combination is not FDA-approved as a product. Individual ingredients (lidocaine, diphenhydramine, antacids) are FDA-approved in other formulations. This preparation is a prescriber-directed, patient-specific 503A compounded preparation.